• 1. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 2. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 5. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates

Research Brief on 2-(cyclopentylcarbamothioyl)sulfanylacetic acid (CAS: 828299-46-3): Recent Advances and Applications

2-(cyclopentylcarbamothioyl)sulfanylacetic acid (CAS: 828299-46-3) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This thiocarbamate derivative exhibits unique structural features that make it valuable for various applications, particularly in drug discovery and development. Recent studies have focused on its potential as a building block for novel therapeutic agents, with particular attention to its role in modulating enzyme activity and its applications in medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry explored the compound's utility as a versatile synthon for the development of enzyme inhibitors. The research team demonstrated that 2-(cyclopentylcarbamothioyl)sulfanylacetic acid could serve as an effective pharmacophore in designing inhibitors for cysteine proteases, which are implicated in numerous disease pathways. The compound's unique structural configuration, featuring both carbamothioyl and sulfanylacetic acid moieties, allows for specific interactions with enzyme active sites.

In the field of antimicrobial research, a recent investigation (Bioorganic Chemistry, 2024) reported promising results when 2-(cyclopentylcarbamothioyl)sulfanylacetic acid was incorporated into novel antibacterial agents. The study found that derivatives of this compound exhibited significant activity against drug-resistant bacterial strains, with MIC values in the range of 2-8 μg/mL against MRSA. The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall biosynthesis through inhibition of key enzymatic processes.

Another significant development involves the application of 828299-46-3 in cancer research. A 2024 preclinical study demonstrated that certain analogs of this compound showed potent antiproliferative effects against various cancer cell lines, including breast (MCF-7) and colon (HT-29) cancer cells. The mechanism of action appears to involve the induction of apoptosis through mitochondrial pathway activation, as evidenced by flow cytometry analysis and caspase activation assays.

The compound's physicochemical properties have also been the subject of recent investigation. Computational studies published in the Journal of Chemical Information and Modeling (2023) provided detailed insights into the molecular dynamics and binding characteristics of 2-(cyclopentylcarbamothioyl)sulfanylacetic acid. These studies revealed favorable drug-like properties, including appropriate lipophilicity (logP ~2.3) and good solubility in physiological conditions, suggesting potential for further pharmaceutical development.

Current research directions include exploring the compound's utility in PROTAC (proteolysis targeting chimera) technology, where its bifunctional nature could facilitate the development of novel targeted protein degraders. Preliminary results from ongoing studies suggest that 828299-46-3 derivatives may serve as effective linkers in these complex molecular constructs, potentially opening new avenues in targeted therapy development.

As research progresses, 2-(cyclopentylcarbamothioyl)sulfanylacetic acid continues to demonstrate significant potential across multiple therapeutic areas. Future studies are expected to further elucidate its mechanisms of action and optimize its pharmacological properties for clinical applications. The compound's versatility and promising biological activity profile position it as an important focus for continued investigation in chemical biology and drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)